Several brokerages have updated their recommendations and price targets on shares of Exact Sciences Corporation (NASDAQ: EXAS) in the last few weeks:

  • 8/4/2017 – Exact Sciences Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “
  • 8/3/2017 – Exact Sciences Corporation was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $38.66 price target on the stock.
  • 8/2/2017 – Exact Sciences Corporation was upgraded by analysts at Vetr from a “sell” rating to a “buy” rating. They now have a $41.07 price target on the stock.
  • 7/26/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at Bank of America Corporation.
  • 7/26/2017 – Exact Sciences Corporation had its price target raised by analysts at Lake Street Capital from $30.00 to $41.00. They now have a “hold” rating on the stock.
  • 7/26/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at Craig Hallum. They now have a $46.00 price target on the stock, up previously from $41.00.
  • 7/26/2017 – Exact Sciences Corporation had its price target raised by analysts at Roth Capital from $40.00 to $46.00. They now have a “buy” rating on the stock.
  • 7/26/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $45.00 price target on the stock, up previously from $42.00.
  • 7/25/2017 – Exact Sciences Corporation was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $36.55 price target on the stock.
  • 7/20/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $42.00 price target on the stock, up previously from $38.00.
  • 7/17/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $45.00 price target on the stock, up previously from $35.00.
  • 7/12/2017 – Exact Sciences Corporation was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $34.70 price target on the stock.
  • 7/7/2017 – Exact Sciences Corporation was given a new $50.00 price target on by analysts at Benchmark Co.. They now have a “buy” rating on the stock.
  • 7/7/2017 – Exact Sciences Corporation had its price target raised by analysts at Craig Hallum from $35.00 to $41.00.
  • 7/6/2017 – Exact Sciences Corporation was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $36.37 price target on the stock.
  • 6/28/2017 – Exact Sciences Corporation was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $37.46 price target on the stock.
  • 6/27/2017 – Exact Sciences Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $39.00 price target on the stock. According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “
  • 6/22/2017 – Exact Sciences Corporation was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2017 – Exact Sciences Corporation was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $37.46 price target on the stock.
  • 6/16/2017 – Exact Sciences Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/13/2017 – Exact Sciences Corporation was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $36.39 price target on the stock.
  • 6/12/2017 – Exact Sciences Corporation had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $38.00 price target on the stock, up previously from $34.00.
  • 6/9/2017 – Exact Sciences Corporation had its price target lowered by analysts at Canaccord Genuity from $40.00 to $38.00. They now have a “buy” rating on the stock.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded up 1.24% during mid-day trading on Monday, hitting $39.17. The stock had a trading volume of 400,176 shares. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $42.18. The firm’s market cap is $4.66 billion. The stock’s 50-day moving average is $36.51 and its 200 day moving average is $27.90.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The business had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities research analysts predict that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the completion of the transaction, the senior vice president now owns 57,603 shares in the company, valued at $2,028,201.63. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the transaction, the chief financial officer now owns 19,861 shares of the company’s stock, valued at approximately $782,722.01. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.